Inter-Institutional Cooperative Laboratories
Laboratory of Cancer Biology
KOBAYASHI Susumu Prof. M.D., Ph.D.
Other Affiliations: Beth Israel Deaconess Medical Center / Harvard Medical School / Tokyo University of Science
Lung cancer, Leukemia, Targeted therapy, Resistance
I received M.D. degree in 1994. After completion of resident and fellowship training, I decided to pursue research career, and received Ph.D. from Kyoto University Graduate School of Medicine in 2003. I established my own independent laboratory in 2009 at Beth Israel Deaconess Medical Center. I joined National Cancer Center and University of Tokyo in 2018 and 2019, respectively. Our goal is to provide all cancer patients with precision and personalized medicine through translational and reverse translational research. We closely collaborate with intramural and extramural clinicians and researchers to cure cancers. Our research focuses are:
The drug response varies from patient to patient even in the same cancer types due to tumor heterogeneity. To provide the best therapeutic option for each patient, which is called “precision medicine”, we need to identify biomarkers to predict the drug response.
Mathematical Modeling of Cancer Initiation and Progression
On the basis of the latest data and accumulated knowledge from clinical and experimental research, we develop a mathematical or computational model of cancer evolution in order to reveal the essence of cancer initiation and progression. Based on the quantitative analysis by theoretical models, we explore the best practice strategies against cancer.
Development of Novel Cancer Therapeutics and Diagnosis
Deeply understanding “Cancer Hallmarks and Vulnerability” is important to discover the target molecules for the novel drug development. Focusing on genomic instability, one of the cancer hallmarks, we are seeking the molecules for the drug discovery to target the vulnerability of cancers. We are committed to apply our findings for development of the innovative cancer therapeutics in global collaboration with academia, biotech, and pharma.
Understandings of Drug Resistance Mechanisms
For a past few decades, molecular-target drugs have been game changers for cancer therapeutic strategies. In most cases, however, these therapies would eventually fail due to acquiring drug resistance. We are one of the first to report the T790M resistant mutation to 1st/2nd generation EGFR tyrosine kinase inhibitors (TKIs) in lung cancer patients with EGFR mutations. This discovery led to development of osimertinib, third generation EGFR TKI. However, intrinsic and acquired resistance to osimertinib remains a major problem in clinic. To overcome these difficulties, we continue to investigate the mechanisms of resistance leading to development of the innovative therapeutic strategies.
|1994. 4.28||M.D. (Japan), Kyoto University, School of Medicine, Kyoto, Japan|
|1994-1995||Internship: Internal Medicine, Kyoto University Hospital, Kyoto, Japan|
|1995-1997||Residency: Internal Medicine, Hyogo Prefectural Amagasaki Hospital, Hyogo, Japan|
|1997-2001||Kyoto University, Graduate School of Medicine, Kyoto, Japan|
|2003.3.24||Ph.D., Kyoto University, Graduate School of Medicine, Kyoto, Japan|
|2002-2006||Postdoctoral Fellow, Department of Medicine, Hematology/Oncology Division, Beth Israel Deaconess Medical Center, Boston, MA|
|2006-2009||Instructor in Medicine, Harvard Medical School, Boston, MA|
|2009-2017||Assistant Professor of Medicine, Harvard Medical School, Boston, MA|
|2016-present||Co-Director, Lung Cancer Research Program, Cancer Research Institute at Beth Israel Deaconess Medical Center, Boston, MA|
|2017-present||Associate Professor of Medicine, Harvard Medical School, Boston, MA|
|2018-present||Chief, Division of Translational Genomics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan|
|2019-present||Adjunct Professor, Graduate School of Frontier Science, The University of Tokyo, Kashiwa, Japan.|